A detailed history of Prentiss Smith & CO Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Prentiss Smith & CO Inc holds 4,500 shares of ABBV stock, worth $856,530. This represents 0.56% of its overall portfolio holdings.

Number of Shares
4,500
Previous 4,500 -0.0%
Holding current value
$856,530
Previous $888,000 10.02%
% of portfolio
0.56%
Previous 0.6%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

SELL
$154.79 - $180.76 $22,754 - $26,571
-147 Reduced 3.16%
4,500 $771,000
Q1 2024

Apr 30, 2024

SELL
$159.82 - $182.1 $64,727 - $73,750
-405 Reduced 8.02%
4,647 $846,000
Q4 2023

Feb 02, 2024

SELL
$137.6 - $154.97 $85,724 - $96,546
-623 Reduced 10.98%
5,052 $782,000
Q3 2023

Oct 24, 2023

SELL
$133.59 - $154.65 $31,393 - $36,342
-235 Reduced 3.98%
5,675 $845,000
Q4 2022

Jan 31, 2023

SELL
$138.31 - $165.87 $51,174 - $61,371
-370 Reduced 5.89%
5,910 $955,000
Q4 2021

Jan 28, 2022

SELL
$107.43 - $135.93 $26,857 - $33,982
-250 Reduced 3.83%
6,280 $850,000
Q4 2020

Feb 03, 2021

SELL
$80.49 - $108.67 $74,614 - $100,737
-927 Reduced 12.43%
6,530 $700,000
Q3 2020

Nov 02, 2020

BUY
$85.91 - $100.83 $213,056 - $250,058
2,480 Added 49.83%
7,457 $653,000
Q1 2020

Apr 29, 2020

SELL
$64.5 - $97.79 $41,925 - $63,563
-650 Reduced 11.55%
4,977 $379,000
Q4 2019

Jan 21, 2020

SELL
$72.13 - $90.25 $22,720 - $28,428
-315 Reduced 5.3%
5,627 $498,000
Q1 2019

Jul 01, 2019

BUY
$77.14 - $90.79 $15,428 - $18,158
200 Added 3.48%
5,942 $479,000
Q1 2018

Apr 20, 2018

BUY
$92.01 - $123.21 $8,464 - $11,335
92 Added 1.63%
5,742 $543,000
Q4 2017

Feb 13, 2018

SELL
$89.56 - $98.21 $116,428 - $127,672
-1,300 Reduced 18.71%
5,650 $546,000
Q3 2017

Oct 23, 2017

BUY
$69.85 - $89.22 $485,457 - $620,079
6,950
6,950 $618,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $337B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Prentiss Smith & CO Inc Portfolio

Follow Prentiss Smith & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prentiss Smith & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prentiss Smith & CO Inc with notifications on news.